{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+agent&page=49", "query": { "intervention": "Targeted agent", "page": 49 }, "page_size": 10 }, "pagination": { "page": 49, "page_size": 10, "total_count": 1323, "total_pages": 133, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+agent&page=50&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+agent&page=48&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T17:45:06.330Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04010357", "title": "Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small-cell Lung Cancer", "Large Cell Neuroendocrine Carcinoma of the Lung", "Extrapulmonary Small Cell Carcinoma" ], "interventions": [ { "name": "Abemaciclib,", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 14, "start_date": "2020-01-13", "completion_date": "2026-04-30", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-11-06T17:45:06.330Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04010357" }, { "nct_id": "NCT00597753", "title": "Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Renal Failure", "Chronic Kidney Disease", "Anemia" ], "interventions": [ { "name": "peginesatide", "type": "DRUG" }, { "name": "Epoetin Alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Affymax", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 803, "start_date": "2007-09", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2013-02-12", "last_synced_at": "2026-11-06T17:45:06.330Z", "location_count": 89, "location_summary": "Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more", "locations": [ { "city": "Paragould", "state": "Arkansas" }, { "city": "Fairfield", "state": "California" }, { "city": "Granada Hills", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00597753" }, { "nct_id": "NCT04592380", "title": "Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dyspnea", "Hypertension", "Acute Heart Failure" ], "interventions": [ { "name": "Stage 1: Clevidipine (double-blinded)", "type": "DRUG" }, { "name": "Stage 1: Placebo (double-blinded)", "type": "DRUG" }, { "name": "Stage 2: Clevidipine (open-label)", "type": "DRUG" }, { "name": "Stage 2: Standard of Care (open-label)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Medicines Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-08", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-11-06T17:45:06.330Z", "location_count": 9, "location_summary": "Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Brooklyn", "state": "New York" }, { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04592380" }, { "nct_id": "NCT03828682", "title": "Veloxis de Novo Kidney Transplant ECSWD", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Kidney Transplantation", "Immunosuppression" ], "interventions": [ { "name": "Tacrolimus Extended Release Oral Tablet [Envarsus]", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Mycophenolic Acid Oral Product", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Simon Tremblay, PharmD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2019-06-21", "completion_date": "2022-06-30", "has_results": false, "last_update_posted_date": "2020-05-13", "last_synced_at": "2026-11-06T17:45:06.330Z", "location_count": 2, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03828682" }, { "nct_id": "NCT03481894", "title": "Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Malnutrition" ], "interventions": [ { "name": "Kabiven®", "type": "DRUG" }, { "name": "Compounded standard parenteral nutrition", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fresenius Kabi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "2 Years to 16 Years" }, "enrollment_count": 0, "start_date": "2018-03", "completion_date": "2021-03", "has_results": false, "last_update_posted_date": "2019-09-04", "last_synced_at": "2026-11-06T17:45:06.330Z", "location_count": 2, "location_summary": "Chicago, Illinois • Kansas City, Missouri", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03481894" }, { "nct_id": "NCT06447662", "title": "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Pancreatic Ductal", "Colorectal Neoplasms", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "PF-07934040", "type": "DRUG" }, { "name": "Gemcitabine", "type": "COMBINATION_PRODUCT" }, { "name": "Nab-paclitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "Cetuximab", "type": "COMBINATION_PRODUCT" }, { "name": "Fluorouracil", "type": "COMBINATION_PRODUCT" }, { "name": "Oxaliplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Leucovorin", "type": "COMBINATION_PRODUCT" }, { "name": "Bevacizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "pemetrexed", "type": "COMBINATION_PRODUCT" }, { "name": "Cisplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Paclitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "Carboplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Sasanlimab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2024-06-27", "completion_date": "2026-10-09", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-06T17:45:06.330Z", "location_count": 26, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06447662" }, { "nct_id": "NCT07223541", "title": "Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Cemiplimab 350 MG Intravenous Solution", "type": "DRUG" }, { "name": "Fianlimab 1600 MG Intravenous Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2026-01-15", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-11-06T17:45:06.330Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT07223541" }, { "nct_id": "NCT02956005", "title": "Envarsus XR in African American Renal Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Renal Transplant Recipients" ], "interventions": [ { "name": "ENVARSUS®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 18, "start_date": "2016-09", "completion_date": "2018-09", "has_results": true, "last_update_posted_date": "2020-03-24", "last_synced_at": "2026-11-06T17:45:06.330Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02956005" }, { "nct_id": "NCT04594941", "title": "A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Coronary Artery Disease (CAD)", "Ischemic Heart Disease" ], "interventions": [ { "name": "Flurpiridaz (18F) Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GE Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2022-01-27", "completion_date": "2022-05-26", "has_results": true, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-11-06T17:45:06.330Z", "location_count": 5, "location_summary": "Hialeah, Florida • Miami, Florida • North Miami Beach, Florida + 2 more", "locations": [ { "city": "Hialeah", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "North Miami Beach", "state": "Florida" }, { "city": "Knoxville", "state": "Tennessee" }, { "city": "Katy", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04594941" }, { "nct_id": "NCT06351683", "title": "Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lower Urinary Tract Symptoms", "Overactive Bladder Syndrome" ], "interventions": [ { "name": "MitoQ (mitoquinol mesylate)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Iman Al-Naggar, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "FEMALE", "summary": "50 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2024-04-03", "completion_date": "2026-04-01", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-11-06T17:45:06.330Z", "location_count": 1, "location_summary": "Farmington, Connecticut", "locations": [ { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06351683" } ] }